相关临床试验
28
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1766
已完成
21
75.0%
招募中
2
7.1%
终止
2
7.1%
Unknown
3
10.7%
暂无批准数据
- The NIH has awarded a first installment of $4.6 million, part of up to $12.8 million over three years, to a multi-university team modeling drug-hormone interactions in women. - Thirteen researchers from Michigan State, Rutgers, Emory, Tulane, and other institutions will build computational models integrating age and reproductive cycle stage into drug predictions. - The project targets metabolic drugs such as metformin, insulin, and GLP-1 agents, whose effects may vary with shifting female hormone levels. - All computer models and data will be freely available worldwide, with findings intended to inform NIH guidelines and national safety standards.
- A Rutgers-led international collaboration identified 36 genes that substantially raise the risk for obsessive-compulsive disorder (OCD) and chronic tic disorders, published in Nature Neuroscience. - The findings dramatically expand the catalog of shared risk genes and reveal biological connections with autism and schizophrenia, highlighting brain circuits governing impulse control, movement, and habit formation. - Researchers say the discovery of over 30 targets opens new possibilities for pharmaceutical treatment development, moving beyond the few strong genes previously known. - The study analyzed DNA from nearly 4,000 affected individuals using whole-exome sequencing, with many risk genes active in the cortex and striatum.
- Concordare Trials closed a funding round led by Surface Ventures, with participation from Techstars, Innovation Works, Gaingels, and individual investors. - The company's AI-powered Concordare Suite converts static protocol PDFs into a structured, interoperable digital format called the Clinical Trial Protocol Model (CTPM). - Manual configuration against non-standardized protocols costs an estimated $25 million per study, a structural gap the platform aims to address. - The workflow can accelerate study activation by 6–8 weeks, helping bring life-saving treatments to patients sooner.
- Portal Innovations has officially opened the New Jersey Innovation Hub (NJIH) inside the HELIX district in New Brunswick, launching with 16 founding member companies — the largest pre-launch cohort in Portal's national network. - The nearly 30,000-square-foot facility provides wet and dry lab space, offices, and over $2 million in lab equipment, supported by a broad public-private partnership including Rutgers University, Johnson & Johnson, RWJBarnabas Health, and the NJEDA. - Founding member companies span diverse fields including T cell therapies for autoimmune diseases, AI-driven medication management, precision oncology, rare ocular disease treatments, and HPV-targeted engineered T cell therapy. - The hub aims to bridge the gap between scientific discovery and commercialization, offering early-stage life sciences companies access to capital, mentorship, and Portal's national network of pharmaceutical partners and research institutions.
- University of Florida Health researchers identified 92 genetic variants that may contribute to adolescent idiopathic scoliosis, a spinal curvature affecting 3% of children worldwide. - The team narrowed an initial pool of 1,664 variants across 26 genomic regions using a massively parallel reporter assay in living cartilage cells. - The findings could eventually enable genetic tests to identify children at high risk, allowing closer monitoring and timely intervention before curvature requires surgery. - The study, published in Genome Research, complements earlier UF Health work comparing gene activity in spinal tissue from AIS patients and unaffected individuals.
- Biopharma competitive advantage is shifting from R&D intensity toward operational readiness, manufacturing capability, and supply chain resilience. - A growing gap exists between the pace of scientific breakthroughs and the commercialization systems needed to deliver therapies at scale. - Integrated ecosystems that connect R&D, manufacturing, logistics, and workforce development are becoming essential for reducing friction in the path to patient access. - Middlesex County, New Jersey exemplifies this model, with over $930 million in annual R&D activity, nearly 47,000 manufacturing workers, and logistics reaching 40% of the U.S. population within one day.
- Tonix Pharmaceuticals has licensed exclusive worldwide rights to TNX-4900, a highly selective Sigma-1 receptor antagonist developed at Rutgers University for treating chronic neuropathic pain. - The compound demonstrated significant analgesic efficacy in preclinical models of diabetic and chemotherapy-induced neuropathic pain without evidence of tolerance or motor impairment. - TNX-4900 binds the human Sigma-1 receptor with nanomolar affinity and exhibits favorable pharmacokinetic properties, including 28% oral bioavailability. - The company plans to advance TNX-4900 through IND-enabling studies, leveraging its experience with FDA-approved non-opioid analgesic TONMYA for fibromyalgia.
- A Rutgers study of 72 adults at risk for metabolic syndrome found that metformin blunts improvements in blood vessel function, fitness, and blood sugar control typically achieved through exercise. - Researchers discovered that while exercise alone improved vascular insulin sensitivity and blood flow to muscles, adding metformin reduced these beneficial effects. - The findings challenge the long-held medical assumption that combining metformin with exercise provides additive benefits for diabetes and heart disease prevention. - Scientists call for new research to determine optimal strategies for combining exercise with metformin, given that nearly 38 million Americans have type 2 diabetes.
